GlaxoSmithKline Consumer Healthcare is looking to restructure its media, marketing and digital units in anticipation of upcoming mega-merger with Pfizer being rubber-stamped later this year. Current marketing boss Carlton Lawson is set to depart and be replaced by EMEA head Tamara Rogers. The deal was announced last December and is still subject to anti-trust approval. If approved, it
Novartis has signalled its intention to change the way it approaches and uses technology, creating a new Chief Digital Officer role and filling it with a former retail executive. The tactic last month was hot on the heels of GSK’s decision to pick former Walmart Chief Information Officer, Karenann Terrell, to be its Chief Digital
Cannes Lions Health coverage provided by Klick Health. While pharma marketing executives were easily outnumbered by ad agency folks at Cannes Lions Health, drugmakers still pulled in big audiences with play-by-play case studies and frank talk. The five pharma presenter, six if pharma trade association PhRMA is included, attacked some weighty questions: Is pharma’s commercial model
GlaxoSmithKline’s mobile app that helps asthma patients understand their condition and how to manage it was one of six winners at the AXA PPP Health Tech & You Awards. The app, MyAsthma, which was developed with UK agency The Earthworks, allows users to track medicine usage and asthma attacks whilst utilising location, weather and air
GSK is sponsoring a new Android mobile app that was created with the aim to raise awareness, educate users and collect health outcomes data relating to the flu and other ailments. The app, Flumoji, was developed by MIT Connection Science, a cross-discipline group from the US Institute, and is being positioned as a ‘health wizard’.
The internet strongly agrees there’s an artificial intelligence (AI) revolution going on, and it is active within pharma marketing. IBM Watson, the AI brain being infused all over healthcare, will form the backend of an interactive display ad for GSK Consumer Healthcare’s Theraflu. The allergy product was one of seven brands, across four beta partners,
GlaxoSmithKline’s plans to incorporate sensors in its inhalers is expected to provide real-time data about the patient experience in a clinical trial, and that may help improve adherence. In November the FDA cleared GSK and Propeller Health to market a custom Propeller sensor with Ellipta, the drugmaker’s COPD medication, for the treatment of asthma and
